Browsing NTNU Open by Author "Helbekkmo, Nina"
Now showing items 1-7 of 7
-
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial
Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; ROGG, LOTTE VICTORIA; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug (Peer reviewed; Journal article, 2022)The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical ... -
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Peer reviewed; Journal article, 2013)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved. Methods: Patients ... -
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Grimsrud, Tom Kristian; Haram, Per Magnus; Helbekkmo, Nina; Helland, Åslaug; Hjelde, Harald Harris; Jakobsen, Bjørn; Møller, Bjørn; Petersen, Martin; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Aanerud, Marianne; Fjellbirkeland, Lars (Peer reviewed; Journal article, 2019)We have studied the alterations in the use of curative treatment and the outcome for lung cancer patients in Norway 2001–2016. The Cancer Registry of Norway has a practically complete registration of all cancer diagnoses, ... -
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Peer reviewed; Journal article, 2014)Introduction: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends
Nilssen, Yngvar; Brustugun, Odd Terje; Fjellbirkeland, Lars; Grønberg, Bjørn Henning; Haram, Per Magnus; Helbekkmo, Nina; Helland, Åslaug; Wahl, Sissel Gyrid Freim; Aanerud, Marianne; Solberg, Steinar (Journal article; Peer reviewed, 2024)Introduction/Background: There has been a marked survival improvement for patients with non–small-cell lung cancer. We describe the national trends in characteristics and survival, and geographical differences in diagnostic ... -
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond-Eirik; Solberg, Steinar (Journal article; Peer reviewed, 2018)Introduction There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are ...